Virtue® SAB

Compelling Clinical Data Out to 3 Years

SABRE Coronary ISR Study: 6-Month Angiographic Results

Demonstrated Efficacy with Low 0.12mm Late Loss (PP)
sabre angiographic results1RVD reported using Internormal values; 2Trial primary performance endpoint; 3Trial secondary performance endpoint (binary restenosis = >50% lumen diameter stenosis)

SABRE Coronary ISR Study: 3 Year Safety Outcomes

Demonstrated Safety with Low Incidence of TLF Out to 3 Years
sabre clinical data1TV-MI: target vessel myocardial infarction; 2TLR: any repeat percutaneous or surgical intervention of target lesion; 3TLF: target lesion failure (per patient composite of cardiac death, TV-MI, and TLR). Primary safety endpoint was TLF @30 days; 4Cause of death unknown - reported as multiple organ failure non-cardiac and non-neurological. Adjudicated as non-device and non-procedure related.

Revised per protocol analysis set meets the criteria of the proposed In-Stent Restenosis IDE study population

Have a question?
Contact us at 917.254.4900 or info@orchestrabiomed.com